As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting papers on pediatric CML and publications from the LMICs.

Read Professor Hughes' CML publications of the month: January 2025

Clinical CML papers

• Bosutinib for the treatment of CML – using it safely: a Podcast
  Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print) 
  – open access publication
• The evolution of treatment-free remission
  Hughes TP et al. Blood, January 2025 (epub ahead of print)
• The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
  Qian Z et al. Bioorg Chem, January 2025 (epub ahead of print)
• Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different?
  Maduado C et al. ESC Heart Fail, January 2025 (epub ahead of print) – open access publication
• Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review
  Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025
• Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
  Li Z et al. Cancer, January 2025 – open access publication
• Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib
  Yu L et al. Cancer, January 2025 – open access publication
• Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid)
  Sasaki K. Cancer, January 2025
• Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
  Kondo T et al. Cancer, January 2025 – open access publication
• Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group
  Giordano U et al. Biomedicines, January 2025 - open access publication
• Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia
  Mayer J et al. Am J Hematol, January 2025 (epub ahead of print) – open access publication
• Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases
  Yousefi A et al. Ann Hematol, January 2025 (epub ahead of print) – open access publication
• Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study
  Szuber N et al. Future Oncol, January 2025 (epub ahead of print) – open access publication
• Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice
  Aleem A et al. Clin Lymphoma Myeloma Leuk, January 2025
• Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy
  Shen Q et al. Leuk Lymphoma, January 2025 (epub ahead of print)

Scientific CML papers

• Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
  Minhajuddin M et al. Haematologica, January 2025 – open access publication
• LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting
  Quijada-Alamo M et al. Haematologica, January 2025 – open access publication
• Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
  Komic H et al. Haematologica, January 2025 – open access publication
• High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia
  Nygren PJ et al. Blood, January 2025 (epub ahead of print)
• Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells
  Rocco S et al. J Clin Med, January 2025 – open access publication
• EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia
  Brunmeier R et al. Leukemia, January 2025 (epub ahead of print) – open access publication

Pediatric papers

• Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
  Seiser E et al. J Mol Diagn, January 2025 (epub ahead of print)

LMIC CML papers

• Haemolytic anemia in a patient of chronic myeloid leukemia: an unrecognised side-effect
  Jamal I et al. Niger Med J, January 2025 – open access publication
• Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric low middle-income country (LMIC) patients
  Bukhari SI et al. Cancer Invest, January 2025 (epub ahead of print)